SBC Medical Group Holdings Incorporated Q2 FY2026 Earnings Call
· Earnings call transcript and AI-powered summary
SBC Medical Group Holdings Q2 2026 Earnings Summary
Financial Highlights (Q2 2026 vs Q2 2025)
- Revenue: $49 million, +13% year-on-year.
- Adjusted EBITDA: $20 million, +32% year-on-year.
- Adjusted EBITDA margin: 41% (profit growth outpaced revenue growth).
- Despite weaker yen headwind (most business in yen), results absorbed currency impact through higher management services revenue from points business expansion post-June 2025 policy change and revised service fees.
Operational Highlights (as of end-June 2026)
- Clinic locations: 287, +34 year-on-year.
- Trailing 12-month customer visits: 6.92 million, +10% year-on-year.
- Year-to-date clinic revenue: +11% year-on-year.
- Same-clinic revenue: +6% year-on-year.
- Q2 average spend per visit: +9% year-on-year.
- First-half aesthetic dermatology transaction value: +19% year-on-year.
- Gorilla Clinic first-half transaction value: $62 million, +19% year-on-year.
- Business mix: 84% aesthetic / 16% non-aesthetic (significant upside potential noted).
Strategic Updates
- Multi-brand aesthetic dermatology acceleration: Renaming Shonan Aesthetic Dermatology to SBC Skin Clinic (2 new locations); adding 3 NEO Skin Clinic and 1 JUN CLINIC locations; launching THE LASER and SBC MEN'S FLASH formats.
Continue Reading
Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.
Upgrade to ProfessionalContinue Reading
Unlock the full earnings call transcript with speaker labels and formatted dialogue.
Upgrade to Professional